Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome

Smita Vaidya, Kristene Gugliuzza, John A. Daller

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background. End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high risk for the development of renal thrombosis without the benefit of anticoagulation therapy. This study examines the efficacy of anticoagulation therapy in this high-risk patient population. Method. Of nine APAS renal-transplant patients, seven were treated with coumadin, whereas two were treated with heparin. Results. Of the two patients treated with heparin, one had early allograft loss, whereas the other patient is doing fine at 5 years posttransplant. Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years posttransplant, two had early allograft loss, the remaining three patients returned to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because of bleeding complications. Conclusions. Anticoagulation therapy is beneficial to some but not all APAS patients. In addition, bleeding complications are a serious side effect of this therapy.

Original languageEnglish (US)
Pages (from-to)1046-1049
Number of pages4
JournalTransplantation
Volume77
Issue number7
DOIs
StatePublished - Apr 15 2004

Fingerprint

Antiphospholipid Syndrome
Chronic Kidney Failure
Warfarin
Therapeutics
Allografts
Heparin
Hemorrhage
Kidney
Dialysis
Thrombosis
Transplants

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. / Vaidya, Smita; Gugliuzza, Kristene; Daller, John A.

In: Transplantation, Vol. 77, No. 7, 15.04.2004, p. 1046-1049.

Research output: Contribution to journalArticle

@article{67e83b22511b4a09a3764de98dd145ba,
title = "Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome",
abstract = "Background. End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high risk for the development of renal thrombosis without the benefit of anticoagulation therapy. This study examines the efficacy of anticoagulation therapy in this high-risk patient population. Method. Of nine APAS renal-transplant patients, seven were treated with coumadin, whereas two were treated with heparin. Results. Of the two patients treated with heparin, one had early allograft loss, whereas the other patient is doing fine at 5 years posttransplant. Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years posttransplant, two had early allograft loss, the remaining three patients returned to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because of bleeding complications. Conclusions. Anticoagulation therapy is beneficial to some but not all APAS patients. In addition, bleeding complications are a serious side effect of this therapy.",
author = "Smita Vaidya and Kristene Gugliuzza and Daller, {John A.}",
year = "2004",
month = "4",
day = "15",
doi = "10.1097/01.TP.0000119157.81765.46",
language = "English (US)",
volume = "77",
pages = "1046--1049",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome

AU - Vaidya, Smita

AU - Gugliuzza, Kristene

AU - Daller, John A.

PY - 2004/4/15

Y1 - 2004/4/15

N2 - Background. End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high risk for the development of renal thrombosis without the benefit of anticoagulation therapy. This study examines the efficacy of anticoagulation therapy in this high-risk patient population. Method. Of nine APAS renal-transplant patients, seven were treated with coumadin, whereas two were treated with heparin. Results. Of the two patients treated with heparin, one had early allograft loss, whereas the other patient is doing fine at 5 years posttransplant. Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years posttransplant, two had early allograft loss, the remaining three patients returned to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because of bleeding complications. Conclusions. Anticoagulation therapy is beneficial to some but not all APAS patients. In addition, bleeding complications are a serious side effect of this therapy.

AB - Background. End-stage renal disease (ESRD) patients with antiphospholipid antibody syndrome (APAS) remain at high risk for the development of renal thrombosis without the benefit of anticoagulation therapy. This study examines the efficacy of anticoagulation therapy in this high-risk patient population. Method. Of nine APAS renal-transplant patients, seven were treated with coumadin, whereas two were treated with heparin. Results. Of the two patients treated with heparin, one had early allograft loss, whereas the other patient is doing fine at 5 years posttransplant. Of the seven 7 patients treated with coumadin, two patients are doing well at 2 and 3 years posttransplant, two had early allograft loss, the remaining three patients returned to dialysis after they were taken off of the coumadin at 6, 12, and 20 months posttransplant because of bleeding complications. Conclusions. Anticoagulation therapy is beneficial to some but not all APAS patients. In addition, bleeding complications are a serious side effect of this therapy.

UR - http://www.scopus.com/inward/record.url?scp=1942420159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942420159&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000119157.81765.46

DO - 10.1097/01.TP.0000119157.81765.46

M3 - Article

C2 - 15087770

AN - SCOPUS:1942420159

VL - 77

SP - 1046

EP - 1049

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 7

ER -